Therapeutics News and Research

RSS

Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions.

7 Mar 2016

Researchers solve structure of key protein in coronaviruses, like MERS and SARS

When the respiratory illness SARS (Severe Acute Respiratory Syndrome) emerged in 2003, it killed at least 775 people before it was contained. Nine years later, MERS (Middle East Respiratory Syndrome) began circulating in the human population—and has gone on to have a 36 percent case fatality rate.

7 Mar 2016

Leukemia researchers uncover protein that allows blood cancers to develop

Walter and Eliza Hall Institute researchers have uncovered a protein that is key to the development of blood cancers caused by a common genetic error.

7 Mar 2016

Cardiac reprogramming could shrink heart scar tissue, improve patients' heart function

Patients with heart failure often have a buildup of scar tissue that leads to a gradual loss of heart function. In a new study published today in the journal Cell Stem Cell, researchers from the University of North Carolina School of Medicine report significant progress toward a novel approach that could shrink the amount of heart scar tissue while replenishing the supply of healthy heart muscle.

4 Mar 2016

Genetic errors may reduce heart attack risk, study finds

To reduce risk of heart attack, the benefits of a healthy lifestyle are clear. But genetics can still stack the deck. Some people's genes bestow a natural advantage — or disadvantage — in protecting against heart disease, the leading cause of death worldwide.

3 Mar 2016

TSRI researchers find way to predict therapeutic potential of stem cells against different diseases

Scientists from the Florida campus of The Scripps Research Institute have for the first time developed a way to predict how a specific type of stem cell will act against different diseases.

2 Mar 2016

Blueberry Therapeutics set to create safe, effective nanomedicines to tackle unmet healthcare needs

Blueberry Therapeutics Ltd, a leading pharmaceutical company focused on the major medical problems of inflammation and infection, are exploring the anti-microbial agenda through the development of new anti-fungal drugs and treatments to tackle this important unmet healthcare need.

2 Mar 2016

Children's Hospital Colorado study outlines preparedness for future enterovirus D68 outbreaks

From August to September 2014, a typically slow time for respiratory viruses, a nationwide outbreak of enterovirus D68 left resources constrained for Children's Hospital Colorado and pediatric organizations throughout the nation.

2 Mar 2016

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

The Centre for Addiction and Mental Health and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.

1 Mar 2016

UAB researchers focus on five key areas to improve care of CVD patients

According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart disease in the United States every year — that's one in every four deaths. The impact of cardiovascular diseases is quite large.

28 Feb 2016

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

The Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, and Humabs BioMed SA, a Swiss antibody therapeutics company, have identified, isolated and characterized two Ebola virus neutralizing monoclonal antibodies from the blood of a survivor of an Ebola infection.

27 Feb 2016

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is currently no cure. NPC primarily strikes children before and during adolescence and affects one in every 150,000 children. The disease causes cholesterol and other lipids to build up in the body's cells, which results in symptoms such as delayed motor development, deterioration of memory and balance, and seizures.

26 Feb 2016

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Therapeutics News and Research

Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

Researchers solve structure of key protein in coronaviruses, like MERS and SARS

Leukemia researchers uncover protein that allows blood cancers to develop

Cardiac reprogramming could shrink heart scar tissue, improve patients' heart function

Genetic errors may reduce heart attack risk, study finds

TSRI researchers find way to predict therapeutic potential of stem cells against different diseases

Blueberry Therapeutics set to create safe, effective nanomedicines to tackle unmet healthcare needs

Children's Hospital Colorado study outlines preparedness for future enterovirus D68 outbreaks

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

UAB researchers focus on five key areas to improve care of CVD patients

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Sangamo presents immunological data from SB-728-T HIV clinical study at CROI 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

New clinical trial launched to test potential drug that could help immune system combat cancer

Novel unit can significantly speed access to specialized care for critically ill patients

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News